Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping. Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy. Provides basic and clinical evidence based on molecular interactions and clinical studies to address the risks and benefits of cancer immunotherapy Presents the results of new immunotherapy trials, discussing the state-of-the-art in different types of cancer Discusses targeted therapies approved by the FDA, along with therapies with clinical potential used in basic studies

Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field. Key Features: Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field Covers the basic principles and science behind cancer immunotherapy and tumor immunology Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs

Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.

?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation discusses the current pre-clinical and clinical ?d T cell landscape. The book not only focuses on the promises of what's to come, but also on the challenges faced by the field. Particular attention is given to summarizing recent advances on what is known about relevant areas of ?d T cell biology on summarizing the 'big picture' clinical situation, an up-to-date systematic clinical trial review covering autologous, allogeneic, engineered and non-engineered therapies, and perspectives on the types of cutting-edge gene-engineering that may be required to enhance the effect-size and durability of therapeutic efficacy. Content provides updated and comprehensive insights into the current state of ?d T cell immunotherapy, including discussions on the promise as well as challenges of the field that is of interest to existing translational ?d T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?d T cell immunotherapy in the clinic or are wishing to familiarize themselves with non-canonical lymphocyte immunotherapy.

?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation discusses the current pre-clinical and clinical ?d T cell landscape. The book not only focuses on the promises of what’s to come, but also on the challenges faced by the field. Particular attention is given to summarizing recent advances on what is known about relevant areas of ?d T cell biology on summarizing the ‘big picture’ clinical situation, an up-to-date systematic clinical trial review covering autologous, allogeneic, engineered and non-engineered therapies, and perspectives on the types of cutting-edge gene-engineering that may be required to enhance the effect-size and durability of therapeutic efficacy. Content provides updated and comprehensive insights into the current state of ?d T cell immunotherapy, including discussions on the promise as well as challenges of the field that is of interest to existing translational ?d T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?d T cell immunotherapy in the clinic or are wishing to familiarize themselves with non-canonical lymphocyte immunotherapy. Addresses the possible advantage of combining ?d T cell–based immunotherapy with conventional chemotherapy or other therapeutic approaches, such as antiangiogenic drugs Provides an up-to-date, well-rounded discussion of a translationally, commercially, and scientifically relevant field Enables users to familiarize themselves with an overview of the most important aspects of the field with ease or gain an up-to-date objective perspective on various aspects of the field Includes helpful illustrative diagrams covering the breadth of the field as carried out by leading experts

NK Cells in Cancer Immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients. Immunotherapy is fast becoming the method of choice for cancer therapy. Although remarkable advances have been made in the field of immunotherapy, there are significant challenges and difficulties ahead since many of the current immunotherapeutic strategies do not provide long-lasting treatment strategies, and therefore are not very effective. Covers CAR/T and CAR/NK and adoptive NK cell therapy with and without T cell therapies Discusses basic biology of NK cells and mouse models of human cancers and the role of NK cells in metastatic cancer and in cancer stem cells Encompasses information on combination therapies using check point inhibition, adoptive transfer of cytotoxic effector cells, chemotherapeutic drugs and activating and inhibitory antibodies

Immune landscape of pancreatic cancer development and drug resistance explores the advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells. With a strong focus on the development of therapeutic methods to improve the survival rates of pancreatic cancer, this book also shows the latest trends in immune targeted approaches for pancreatic cancer treatment. In 12 chapters Immune landscape of pancreatic cancer development and drug resistance discusses the current understanding of PC development and its various mutational and immune features and explore some of the new immune-based therapies aimed at targeting pancreatic cancer. It covers the urgent need for developing novel therapeutic modalities and aims at delineating future fields and avenues of research in pancreatic cancer treatment. The book provides the reader with an updated understanding of the immune landscape of PC and an all-encompassing overview of the latest trends in immune targeted approaches for PC treatment. This book is a valuable resource for health professionals, scientists and researchers, students, and all those who wish to broaden their knowledge of the advances in immunotherapy in pancreatic cancer. Summarizes the potential combination strategies and latest clinical trials in pancreatic cancer Provides an in-depth overview of our current understanding of pancreatic cancer development, including its mutational and immune features Explores some of the new immune-based therapies aimed at targeting PC Shows pancreatic cancer progression and basic elements in tumor microenvironments and their role in PC progression, also covering immunotherapy strategies